Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06671132Phase 2Recruiting

Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)

Role: lead

NCT06434818Phase 2Recruiting

Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

Role: lead

NCT06218407Phase 1Completed

Development and Evaluation of Computerized Chemosensory Based Orbitofrontal Networks Training for Treatment of Pain

Role: lead

NCT05122598Phase 2Unknown

Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease

Role: lead

NCT04850664Phase 2Unknown

Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder

Role: lead

All 5 trials loaded